Skip to main content
Top
Published in: Diabetologia 5/2010

01-05-2010 | Article

Ablation of AMP-activated protein kinase α1 and α2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo

Authors: G. Sun, A. I. Tarasov, J. McGinty, A. McDonald, G. da Silva Xavier, T. Gorman, A. Marley, P. M. French, H. Parker, F. Gribble, F. Reimann, O. Prendiville, R. Carzaniga, B. Viollet, I. Leclerc, G. A. Rutter

Published in: Diabetologia | Issue 5/2010

Login to get access

Abstract

Aims/hypothesis

AMP-activated protein kinase (AMPK) is an evolutionarily conserved enzyme and a target of glucose-lowering agents, including metformin. However, the precise role or roles of the enzyme in controlling insulin secretion remain uncertain.

Methods

The catalytic α1 and α2 subunits of AMPK were ablated selectively in mouse pancreatic beta cells and hypothalamic neurons by breeding Ampkα1 [also known as Prkaa1]-knockout mice, bearing floxed Ampkα2 [also known as Prkaa2] alleles (Ampkα1 −/− ,α2 fl/fl ,), with mice expressing Cre recombinase under the rat insulin promoter (RIP2). RIP2 was used to express constitutively activated AMPK selectively in beta cells in transgenic mice. Food intake, body weight and urinary catecholamines were measured using metabolic cages. Glucose and insulin tolerance were determined after intraperitoneal injection. Beta cell mass and morphology were analysed by optical projection tomography and confocal immunofluorescence microscopy, respectively. Granule docking, insulin secretion, membrane potential and intracellular free Ca2+ were measured with standard techniques.

Results

Trigenic Ampkα1 −/− ,α2 fl/fl expressing Cre recombinase and lacking both AMPKα subunits in the beta cell, displayed normal body weight and increased insulin sensitivity, but were profoundly insulin-deficient. Secreted catecholamine levels were unchanged. Total beta cell mass was unaltered, while mean islet and beta cell volume were reduced. AMPK-deficient beta cells displayed normal glucose-induced changes in membrane potential and intracellular free Ca2+, while granule docking and insulin secretion were enhanced. Conversely, βAMPK transgenic mice were glucose-intolerant and displayed defective insulin secretion.

Conclusions/interpretation

Inhibition of AMPK activity within the beta cell is necessary, but not sufficient for stimulation of insulin secretion by glucose to occur. AMPK activation in extrapancreatic RIP2.Cre-expressing cells might also influence insulin secretion in vivo.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shaw RJ, Lamia KA, Vasquez D et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642–1646CrossRefPubMed Shaw RJ, Lamia KA, Vasquez D et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642–1646CrossRefPubMed
2.
go back to reference Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328–341CrossRefPubMed Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328–341CrossRefPubMed
3.
go back to reference Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW (1999) 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48:1667–1671CrossRefPubMed Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW (1999) 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48:1667–1671CrossRefPubMed
4.
go back to reference Salt IP, Johnson G, Ashcroft SJ, Hardie DG (1998) AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J 335:533–539PubMed Salt IP, Johnson G, Ashcroft SJ, Hardie DG (1998) AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J 335:533–539PubMed
5.
go back to reference da Silva XG, Leclerc I, Salt IP et al (2000) Role of AMP-activated protein kinase in the regulation by glucose of islet beta-cell gene expression. Proc Natl Acad Sci U S A 97:4023–4028CrossRef da Silva XG, Leclerc I, Salt IP et al (2000) Role of AMP-activated protein kinase in the regulation by glucose of islet beta-cell gene expression. Proc Natl Acad Sci U S A 97:4023–4028CrossRef
6.
go back to reference da Silva XG, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA (2003) Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 371:761–774CrossRef da Silva XG, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA (2003) Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 371:761–774CrossRef
7.
go back to reference Rutter GA, Leclerc I (2009) The AMP-regulated kinase family: Enigmatic targets for diabetes therapy. Mol Cell Endocrinol 297:41–49CrossRefPubMed Rutter GA, Leclerc I (2009) The AMP-regulated kinase family: Enigmatic targets for diabetes therapy. Mol Cell Endocrinol 297:41–49CrossRefPubMed
8.
go back to reference Long YC, Zierath JR (2006) AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116:1776–1783CrossRefPubMed Long YC, Zierath JR (2006) AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116:1776–1783CrossRefPubMed
9.
go back to reference Stapleton D, Woollatt E, Mitchelhill KI et al (1997) AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett 409:452–456CrossRefPubMed Stapleton D, Woollatt E, Mitchelhill KI et al (1997) AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett 409:452–456CrossRefPubMed
10.
go back to reference Hardie DG, Carling D (1997) The AMP-activated protein kinase—fuel gauge of the mammalian cell? Eur J Biochem 246:259–273CrossRefPubMed Hardie DG, Carling D (1997) The AMP-activated protein kinase—fuel gauge of the mammalian cell? Eur J Biochem 246:259–273CrossRefPubMed
11.
go back to reference Viollet B, Andreelli F, Jorgensen SB et al (2003) Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans 31:216–219CrossRefPubMed Viollet B, Andreelli F, Jorgensen SB et al (2003) Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans 31:216–219CrossRefPubMed
12.
go back to reference Jorgensen SB, Viollet B, Andreelli F et al (2004) Knockout of the α2 but not α1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 279:1070–1079CrossRefPubMed Jorgensen SB, Viollet B, Andreelli F et al (2004) Knockout of the α2 but not α1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 279:1070–1079CrossRefPubMed
13.
go back to reference Viollet B, Andreelli F, Jorgensen SB et al (2003) The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 111:91–98PubMed Viollet B, Andreelli F, Jorgensen SB et al (2003) The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 111:91–98PubMed
14.
go back to reference Leclerc I, Woltersdorf WW, da Silva XG et al (2004) Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 286:E1023–E1031CrossRefPubMed Leclerc I, Woltersdorf WW, da Silva XG et al (2004) Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 286:E1023–E1031CrossRefPubMed
15.
go back to reference Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM (2006) Over-expression of AMP-activated protein kinase impairs pancreatic beta-cell function in vivo. J Endocrinol 187:225–235CrossRef Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM (2006) Over-expression of AMP-activated protein kinase impairs pancreatic beta-cell function in vivo. J Endocrinol 187:225–235CrossRef
16.
go back to reference Tsuboi T, da Silva XG, Leclerc I, Rutter GA (2003) 5′ AMP-activated protein kinase controls insulin-containing secretory vesicle dynamics. J Biol Chem 278:52042–52051CrossRefPubMed Tsuboi T, da Silva XG, Leclerc I, Rutter GA (2003) 5′ AMP-activated protein kinase controls insulin-containing secretory vesicle dynamics. J Biol Chem 278:52042–52051CrossRefPubMed
17.
go back to reference McDonald A, Fogarty S, Leclerc I, Hill E, Hardie DG, Rutter GA (2009) Control of insulin granule dynamics by AMPK-dependent KLC1 phosphorylation. Islets 1:1–11CrossRef McDonald A, Fogarty S, Leclerc I, Hill E, Hardie DG, Rutter GA (2009) Control of insulin granule dynamics by AMPK-dependent KLC1 phosphorylation. Islets 1:1–11CrossRef
18.
go back to reference Kefas BA, Heimberg H, Vaulont S et al (2003) AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia 46:250–254PubMed Kefas BA, Heimberg H, Vaulont S et al (2003) AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia 46:250–254PubMed
19.
go back to reference Riboulet-Chavey A, Diraison F, Siew LK, Wong FS, Rutter GA (2008) Inhibition of AMP-activated protein kinase protects pancreatic β-cells from cytokine-mediated apoptosis and CD8+ T cell-induced cytotoxicity. Diabetes 57:415–423CrossRefPubMed Riboulet-Chavey A, Diraison F, Siew LK, Wong FS, Rutter GA (2008) Inhibition of AMP-activated protein kinase protects pancreatic β-cells from cytokine-mediated apoptosis and CD8+ T cell-induced cytotoxicity. Diabetes 57:415–423CrossRefPubMed
20.
go back to reference Jones RG, Plas DR, Kubek S et al (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18:283–293CrossRefPubMed Jones RG, Plas DR, Kubek S et al (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18:283–293CrossRefPubMed
21.
go back to reference Gleason CE, Lu D, Witters LA, Newgard CB, Birnbaum MJ (2007) The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem 282:10341–10351CrossRefPubMed Gleason CE, Lu D, Witters LA, Newgard CB, Birnbaum MJ (2007) The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem 282:10341–10351CrossRefPubMed
22.
go back to reference Minokoshi Y, Alquier T, Furukawa N et al (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569–574CrossRefPubMed Minokoshi Y, Alquier T, Furukawa N et al (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569–574CrossRefPubMed
23.
go back to reference McCrimmon RJ, Fan X, Cheng H et al (2006) Activation of AMP-activated protein kinase within the ventromedial hypothalamus amplifies counterregulatory hormone responses in rats with defective counterregulation. Diabetes 55:1755–1760CrossRefPubMed McCrimmon RJ, Fan X, Cheng H et al (2006) Activation of AMP-activated protein kinase within the ventromedial hypothalamus amplifies counterregulatory hormone responses in rats with defective counterregulation. Diabetes 55:1755–1760CrossRefPubMed
24.
go back to reference McCrimmon RJ, Shaw M, Fan X et al (2008) Key role for AMP-activated protein kinase in the ventromedial hypothalamus in regulating counterregulatory hormone responses to acute hypoglycemia. Diabetes 57:444–450CrossRefPubMed McCrimmon RJ, Shaw M, Fan X et al (2008) Key role for AMP-activated protein kinase in the ventromedial hypothalamus in regulating counterregulatory hormone responses to acute hypoglycemia. Diabetes 57:444–450CrossRefPubMed
25.
go back to reference Claret M, Smith MA, Batterham RL et al (2007) AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J Clin Invest 117:2325–2336CrossRefPubMed Claret M, Smith MA, Batterham RL et al (2007) AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J Clin Invest 117:2325–2336CrossRefPubMed
26.
go back to reference Mountjoy PD, Bailey SJ, Rutter GA (2007) Inhibition by glucose or leptin of neuropeptide Y-expressing hypothalamic neurons requires changes in AMP-activated protein kinase activity. Diabetologia 50:168–177CrossRefPubMed Mountjoy PD, Bailey SJ, Rutter GA (2007) Inhibition by glucose or leptin of neuropeptide Y-expressing hypothalamic neurons requires changes in AMP-activated protein kinase activity. Diabetologia 50:168–177CrossRefPubMed
27.
go back to reference Canabal DD, Song Z, Potian JG, Beuve A, McArdle JJ, Routh VH (2006) Glucose, insulin and leptin signaling pathways modulate nitric oxide (NO) synthesis in glucose-inhibited (GI) neurons in the ventromedial hypothalamus (VMH). Am J Physiol Regul Integr Comp Physiol 292:R1418–R1428PubMed Canabal DD, Song Z, Potian JG, Beuve A, McArdle JJ, Routh VH (2006) Glucose, insulin and leptin signaling pathways modulate nitric oxide (NO) synthesis in glucose-inhibited (GI) neurons in the ventromedial hypothalamus (VMH). Am J Physiol Regul Integr Comp Physiol 292:R1418–R1428PubMed
28.
go back to reference Wyatt CN, Mustard KJ, Pearson SA et al (2007) AMP-activated protein kinase mediates carotid body excitation by hypoxia. J Biol Chem 282:8092–8098CrossRefPubMed Wyatt CN, Mustard KJ, Pearson SA et al (2007) AMP-activated protein kinase mediates carotid body excitation by hypoxia. J Biol Chem 282:8092–8098CrossRefPubMed
29.
go back to reference Choudhury AI, Heffron H, Smith MA et al (2005) The role of insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest 115:940–950PubMed Choudhury AI, Heffron H, Smith MA et al (2005) The role of insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest 115:940–950PubMed
30.
go back to reference Lee JY, Ristow M, Lin X, White MF, Magnuson MA, Hennighausen L (2006) RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J Biol Chem 281:2649–2653CrossRefPubMed Lee JY, Ristow M, Lin X, White MF, Magnuson MA, Hennighausen L (2006) RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function. J Biol Chem 281:2649–2653CrossRefPubMed
31.
go back to reference Pomplun D, Florian S, Schulz T, Pfeiffer AF, Ristow M (2007) Alterations of pancreatic beta-cell mass and islet number due to Ins2-controlled expression of Cre recombinase: RIP-Cre revisited; part 2. Horm Metab Res 39:336–340CrossRefPubMed Pomplun D, Florian S, Schulz T, Pfeiffer AF, Ristow M (2007) Alterations of pancreatic beta-cell mass and islet number due to Ins2-controlled expression of Cre recombinase: RIP-Cre revisited; part 2. Horm Metab Res 39:336–340CrossRefPubMed
32.
go back to reference Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM (2008) Glucose-sensing in L-cells: a primary cell study. Cell Metabolism 8:532–539CrossRefPubMed Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM (2008) Glucose-sensing in L-cells: a primary cell study. Cell Metabolism 8:532–539CrossRefPubMed
33.
go back to reference Nicolson TJ, Bellomo EA, Wijesekara N et al (2009) Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. Diabetes 58:2070–2083CrossRefPubMed Nicolson TJ, Bellomo EA, Wijesekara N et al (2009) Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. Diabetes 58:2070–2083CrossRefPubMed
34.
go back to reference Rahier J, Goebbels RM, Henquin JC (1983) Cellular composition of the human diabetic pancreas. Diabetologia 24:366–371CrossRefPubMed Rahier J, Goebbels RM, Henquin JC (1983) Cellular composition of the human diabetic pancreas. Diabetologia 24:366–371CrossRefPubMed
35.
go back to reference Cerasi E, Effendic S, Luft R (1969) Role of adrenergic receptors in glucose-induced insulin secretion in man. Lancet 2:301–302CrossRefPubMed Cerasi E, Effendic S, Luft R (1969) Role of adrenergic receptors in glucose-induced insulin secretion in man. Lancet 2:301–302CrossRefPubMed
36.
go back to reference Alanentalo T, Asayesh A, Morrison H et al (2007) Tomographic molecular imaging and 3D quantification within adult mouse organs. Nat Methods 4:31–33CrossRefPubMed Alanentalo T, Asayesh A, Morrison H et al (2007) Tomographic molecular imaging and 3D quantification within adult mouse organs. Nat Methods 4:31–33CrossRefPubMed
37.
go back to reference Williams T, Brenman JE (2008) LKB1 and AMPK in cell polarity and division. Trends Cell Biol 18:193–198CrossRefPubMed Williams T, Brenman JE (2008) LKB1 and AMPK in cell polarity and division. Trends Cell Biol 18:193–198CrossRefPubMed
38.
go back to reference Fu A, Ng AC, Depatie C et al (2009) Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 10:285–295CrossRefPubMed Fu A, Ng AC, Depatie C et al (2009) Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 10:285–295CrossRefPubMed
39.
go back to reference Granot Z, Swisa A, Magenheim J et al (2009) LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab 10:296–308CrossRefPubMed Granot Z, Swisa A, Magenheim J et al (2009) LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab 10:296–308CrossRefPubMed
40.
go back to reference Shaw RJ (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 196:65–80CrossRef Shaw RJ (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 196:65–80CrossRef
41.
go back to reference Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16:1472–1487CrossRefPubMed Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16:1472–1487CrossRefPubMed
42.
go back to reference Thorens B, Sarkar HK, Kaback HR, Lodish HF (1988) Cloning and functional expression in bacteria of a novel glucose transporter present in liver intestine kidney and B-pancreatic islet cells. Cell 55:281–290CrossRefPubMed Thorens B, Sarkar HK, Kaback HR, Lodish HF (1988) Cloning and functional expression in bacteria of a novel glucose transporter present in liver intestine kidney and B-pancreatic islet cells. Cell 55:281–290CrossRefPubMed
43.
go back to reference Ahren B, Simonsson E, Scheurink AJ, Mulder H, Myrsen U, Sundler F (1997) Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46:97–106CrossRefPubMed Ahren B, Simonsson E, Scheurink AJ, Mulder H, Myrsen U, Sundler F (1997) Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46:97–106CrossRefPubMed
44.
go back to reference Gannon M, Shiota C, Postic C, Wright CVE, Magnuson M (2000) Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 26:139–142CrossRefPubMed Gannon M, Shiota C, Postic C, Wright CVE, Magnuson M (2000) Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 26:139–142CrossRefPubMed
45.
go back to reference Kefas BA, Cai Y, Ling Z et al (2003) AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 30:151–161CrossRefPubMed Kefas BA, Cai Y, Ling Z et al (2003) AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 30:151–161CrossRefPubMed
46.
go back to reference Kefas BA, Cai Y, Kerckhofs K et al (2004) Metformin-induced stimulation of AMP-activated protein kinase in b-cells impairs their glucose-responsiveness and can lead to apoptosis. Biochem Pharmacol 68:409–416CrossRefPubMed Kefas BA, Cai Y, Kerckhofs K et al (2004) Metformin-induced stimulation of AMP-activated protein kinase in b-cells impairs their glucose-responsiveness and can lead to apoptosis. Biochem Pharmacol 68:409–416CrossRefPubMed
47.
go back to reference Lim A, Park SH, Sohn JW et al (2009) Glucose deprivation regulates KATP channel trafficking via AMP-activated protein kinase (AMPK) in pancreatic β-cells. Diabetes 58:2813–2819CrossRefPubMed Lim A, Park SH, Sohn JW et al (2009) Glucose deprivation regulates KATP channel trafficking via AMP-activated protein kinase (AMPK) in pancreatic β-cells. Diabetes 58:2813–2819CrossRefPubMed
48.
go back to reference Targonsky ED, Dai F, Koshkin V et al (2006) alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia 49:1587–1598CrossRefPubMed Targonsky ED, Dai F, Koshkin V et al (2006) alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia 49:1587–1598CrossRefPubMed
49.
go back to reference Hezel AF, Gurumurthy S, Granot Z et al (2008) Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol 28:2414–2425CrossRefPubMed Hezel AF, Gurumurthy S, Granot Z et al (2008) Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol 28:2414–2425CrossRefPubMed
50.
go back to reference Buren J, Liu HX, Lauritz J, Eriksson JW (2003) High glucose and insulin in combination cause insulin receptor substrate-1 and -2 depletion and protein kinase B desensitisation in primary cultured rat adipocytes: possible implications for insulin resistance in type 2 diabetes. Eur J Endocrinol 148:157–167CrossRefPubMed Buren J, Liu HX, Lauritz J, Eriksson JW (2003) High glucose and insulin in combination cause insulin receptor substrate-1 and -2 depletion and protein kinase B desensitisation in primary cultured rat adipocytes: possible implications for insulin resistance in type 2 diabetes. Eur J Endocrinol 148:157–167CrossRefPubMed
51.
go back to reference Kalra SP (2008) Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches. Nutrition 24:820–826CrossRefPubMed Kalra SP (2008) Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches. Nutrition 24:820–826CrossRefPubMed
Metadata
Title
Ablation of AMP-activated protein kinase α1 and α2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo
Authors
G. Sun
A. I. Tarasov
J. McGinty
A. McDonald
G. da Silva Xavier
T. Gorman
A. Marley
P. M. French
H. Parker
F. Gribble
F. Reimann
O. Prendiville
R. Carzaniga
B. Viollet
I. Leclerc
G. A. Rutter
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1692-1

Other articles of this Issue 5/2010

Diabetologia 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.